Edgewise Therapeutics (EWTX) vs IDEAYA Biosciences (IDYA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Edgewise Therapeutics (EWTX) has outperformed IDEAYA Biosciences (IDYA) over the past year, gaining 155.6% versus a gain of 34.4%. Over five years, EWTX leads with a +123.1% price change compared with +55.9% for IDYA. Edgewise Therapeutics is the larger company by market cap ($4.26 billion vs $3.48 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EWTX | IDYA |
|---|---|---|
| Share price | $39.23 | $36.06 |
| Market cap | $4.26B | $3.48B |
| 1-day change | -0.86% | -0.55% |
| YTD return | +58.09% | +4.31% |
| 1-year return | +155.57% | +34.35% |
| 5-year return | +123.06% | +55.90% |
| EPS (TTM) | $-1.86 | $-1.94 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $218.71M |
| Revenue growth (YoY) | — | +3024.43% |
| Net income (latest FY) | $-167.79M | $-113.70M |
| Operating margin | — | -72.84% |
| Net margin | — | -51.99% |
| 52-week high | $48.51 | $42.68 |
| 52-week low | $14.25 | $26.05 |
| Distance from 52-week high | -19.13% | -15.51% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +34.13% | +46.28% |
| Average volume | 1.34M | 779.15K |
| Shares outstanding | 108.60M | 96.49M |
| Employees | 127 | 145 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EWTX has outperformed IDYA by 121.2 percentage points over the past year.
About Edgewise Therapeutics
EWTX stock →Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, sevasemten, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
Healthcare · Biotechnology · 127 employees
About IDEAYA Biosciences
IDYA stock →IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings.
Healthcare · Biotechnology · 145 employees
EWTX vs IDYA FAQ
Which is bigger, Edgewise Therapeutics or IDEAYA Biosciences?
Edgewise Therapeutics (EWTX) is larger, with a market capitalization of $4.26B compared with $3.48B for IDEAYA Biosciences (IDYA).
Which stock has performed better over the past year, EWTX or IDYA?
EWTX returned +155.57% over the past 12 months, compared with +34.35% for IDYA (price return, excluding dividends). Past performance does not predict future results.
Are Edgewise Therapeutics and IDEAYA Biosciences in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.